Trial Profile
A Study of Granix to Disrupt the Bone Marrow Microenvironment in Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplantation
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 27 Nov 2019
Price :
$35
*
At a glance
- Drugs Filgrastim (Primary) ; Melphalan
- Indications Multiple myeloma
- Focus Therapeutic Use
- 15 Nov 2019 Status changed from active, no longer recruiting to discontinued.
- 04 Dec 2018 This study was halted for futility, as reportd in an abstract presented at the 60th Annual Meeting and Exposition of the American Society of Hematology
- 04 Dec 2018 Results presented at the 60th Annual Meeting and Exposition of the American Society of Hematology